Changes in Management Of Karo Bio AB

Regulatory News:

Karo Bio AB (publ)(STO:KARO) today announced that Jens Kristensen, Chief Medical Officer and Vice President Preclinical Development and Regulatory affairs, leaves his position.

Acting President and CEO Per Bengtsson will temporarily assume management responsibility for clinical development and regulatory affairs until a new Chief Medical Officer has been recruited. The change in management will not affect the clinical development plan of eprotirome.

About Karo Bio Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for unmet medical needs. Karo Bio’s vision is to become a pharmaceutical company with sustainable profitability, commercial products and a competitive project portfolio.

Karo Bio runs a number of drug development projects within the indication areas cardiovascular and metabolic diseases, neuropsychiatry, inflammation, autoimmune diseases, cancer and women’s health. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Important processes and competencies within the company include research, drug development, medical and regulatory expertise.

In addition to proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies. The company’s goals through 2014 are to submit an application for marketing approval of eprotirome for HeFH in EU, and to generate three clinical development projects from its other operations.

Karo Bio is based in Huddinge, Sweden. The company has around 70 employees and since 1998 is listed on NASDAQ OMX Stockholm.

This press release is also available online at www.karobio.com and www.newsroom.cision.com

This information was brought to you by Cision http://www.cisionwire.com